Chemical and analytical services are now widely available to the biomedical community. This accentuates the obligation of the Core to remain cost-effective to its users and to the NIH alike. While offering peptides of substantially higher purity, the Core's charges have remained comparable on a per-residue basis to the advertised commercial products. Especially important is the favorable cost differential for more complex peptides such as the long-acting """"""""M""""""""-PTH analogs and b-amino acid modifications needed under Project I. Savings are also being realized through our capability to perform syntheses on different scales, ranging from .002-.005 to 0.5 mmol, enabling costs to be matched with required quantity. The assets of the facility extend well beyond price considerations alone, however. The Core's staff has worked together for many years, and (starting with Drs. Potts and Keutmann) represents experience reaching back to the earliest days of protein sequencing and synthesis. Mr. Khatri brings broad expertise in contemporary synthetic and analytical methodology, having led us for over 20 years through the transition from t-BOC to Fmoc chemistry, the ongoing adoption of multiple-synthesis instrumentation, and innovative use of specialized protecting groups and coupling methodologies. Important among the """"""""value-added"""""""" benefits of an in-house Core facility is its ability to develop methodologies, not readily available on a commercial basis, in response to investigator needs--such as the long-acting pharmacokinetic analogs under Project I as noted above. This, and the very nature of peptide and protein chemistry, calls for extensive consultative interactions between investigators and Core staff. Updates on progress are available at any stage of the synthesis or analytical process--something not possible when ordering, catalog-style, from an outside vendor. Further, because of the Program Project's commitment of salaries and equipment to the Core, Program Project users receive a priority that assures faster service than is typically available commercially, especially for the longer and more complex peptides often required by Program investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
2P01DK011794-46
Application #
8659694
Study Section
Special Emphasis Panel (ZDK1-GRB-J (O1))
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
46
Fiscal Year
2014
Total Cost
$131,462
Indirect Cost
$55,909
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Christov, Marta; Clark, Abbe R; Corbin, Braden et al. (2018) Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities. JCI Insight 3:
Dedic, Christopher; Hung, Tin Shing; Shipley, Alan M et al. (2018) Calcium fluxes at the bone/plasma interface: Acute effects of parathyroid hormone (PTH) and targeted deletion of PTH/PTH-related peptide (PTHrP) receptor in the osteocytes. Bone 116:135-143
Mizuhashi, Koji; Ono, Wanida; Matsushita, Yuki et al. (2018) Resting zone of the growth plate houses a unique class of skeletal stem cells. Nature 563:254-258
Hanna, Patrick; Grybek, Virginie; Perez de Nanclares, Guiomar et al. (2018) Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. J Bone Miner Res 33:1480-1488
Wein, Marc N; Foretz, Marc; Fisher, David E et al. (2018) Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab 29:723-735
Bastepe, Murat (2018) GNAS mutations and heterotopic ossification. Bone 109:80-85
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338
Cheloha, Ross W; Chen, Bingming; Kumar, Niyanta N et al. (2017) Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad ? Residue Distribution. J Med Chem 60:8816-8833

Showing the most recent 10 out of 215 publications